<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848312</url>
  </required_header>
  <id_info>
    <org_study_id>WIRBÂ® Protocol #20182630</org_study_id>
    <secondary_id>1R56AG058234-01A1</secondary_id>
    <secondary_id>1R01AG070349-01</secondary_id>
    <nct_id>NCT03848312</nct_id>
  </id_info>
  <brief_title>Preventing Alzheimer's With Cognitive Training</brief_title>
  <acronym>PACT</acronym>
  <official_title>Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dementia is the most expensive medical condition in the US and increases in prevalence with&#xD;
      age. More than 5 million Americans have Alzheimer's disease, the most common form of&#xD;
      dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging&#xD;
      and Alzheimer's disease or another type of dementia, and is indicative of higher risk for&#xD;
      dementia. In addition to the obvious health and quality-of-life ramifications of dementia,&#xD;
      there are high direct (e.g., subsidizing residential care needs) and indirect (e.g., lost&#xD;
      productivity of family caregivers) economic costs. Implementing interventions to prevent MCI&#xD;
      and dementia among older adults is of critical importance to health and maintained&#xD;
      quality-of-life for millions of Americans. Recent data analyses from the Advanced Cognitive&#xD;
      Training in Vital Elderly study (ACTIVE) indicate that a specific cognitive intervention,&#xD;
      speed of processing training (SPT), significantly delays the incidence of cognitive&#xD;
      impairment across 10 years. The primary contribution of the proposed research will be the&#xD;
      determination of whether this cognitive training technique successfully delays the onset of&#xD;
      clinically defined MCI or dementia across three years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preventing Alzheimer's Disease with Cognitive Training: The PACT Trial&#xD;
&#xD;
      The primary objective in the R56 phase was to establish the feasibility of the proposed field&#xD;
      trial including meeting participant enrollment goals. The feasibility of the field trial was&#xD;
      established by accruing 1000 enrolled participants. The secondary objective in the R56 phase&#xD;
      was to ascertain participants' willingness to enroll in a longitudinal clinical trial and to&#xD;
      subsequently complete a multispecialty clinical diagnostic evaluation, psychometric testing,&#xD;
      MRI, PET scan, and genetic testing. Participants' willingness to allow access to medicare&#xD;
      records was also determined.&#xD;
&#xD;
      The trial is being expanded in the R01 phase with the goal of enrolling 7600 participants.&#xD;
&#xD;
      The primary goal is to ascertain the effectiveness of cognitive speed of processing training&#xD;
      (SPT) to reduce the incidence of Mild Cognitive Impairment (MCI) or dementia.&#xD;
&#xD;
      Design and Outcomes: A randomized clinical trial among 7600 adults 65 years of age and older&#xD;
      will be completed in order to test the effectiveness of computerized cognitive speed of&#xD;
      processing training (SPT) to reduce incidence of MCI or dementia.&#xD;
&#xD;
      Participants will be screened with an inclusion/exclusion questionnaire and those potentially&#xD;
      eligible will complete brief memory screening, depression screening, and other&#xD;
      questionnaires. Those eligible will be randomized to one of two conditions of brain games and&#xD;
      will complete at least two in-person, supervised training sessions. Additional exercises will&#xD;
      be completed at-home over the next 3 to 5 months followed by booster sessions 1- and 2-years&#xD;
      later.&#xD;
&#xD;
      Participants are asked to initially complete 25 sessions of training and will be asked&#xD;
      complete an additional 10 sessions of booster training 1- and 2- years later. Participants&#xD;
      are instructed to complete 2-3 sessions of training per week until 25 sessions are completed.&#xD;
      At 1- year and again at 2-years, participants will be instructed to complete an additional 10&#xD;
      sessions of training.&#xD;
&#xD;
      Sample Size and Population: Adults 65 years of age and older (N=7600) will be randomly&#xD;
      assigned to SPT (n=3800) or the active comparator condition (n=3800).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of mild cognitive impairment or dementia</measure>
    <time_frame>Three years</time_frame>
    <description>clinical diagnosis of mild cognitive impairment or dementia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7600</enrollment>
  <condition>Age-related Cognitive Decline</condition>
  <condition>Alzheimer's Disease and Related Dementias</condition>
  <arm_group>
    <arm_group_label>Computerized Cognitive Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete computerized cognitive training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Computerized Cognitive Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will complete cognitively-stimulating computer activities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Training</intervention_name>
    <description>Participants will be completing a total of 45 computerized sessions.</description>
    <arm_group_label>Computerized Cognitive Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Computerized Cognitive Stimulation</intervention_name>
    <description>Participants will be completing a total of 45 computerized cognitive stimulation sessions.</description>
    <arm_group_label>Computerized Cognitive Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be age 65 or older at time of consent&#xD;
&#xD;
          -  Have ability to speak and understand English or Spanish&#xD;
&#xD;
          -  Report adequate sensorimotor capacity to perform the computer exercises&#xD;
&#xD;
          -  Report adequate visual capacity to read from a computer screen at a typical viewing&#xD;
             distance&#xD;
&#xD;
          -  Show adequate auditory capacity to understand conversational speech&#xD;
&#xD;
          -  Show adequate motor capacity to touch a computer screen or control a computer mouse.&#xD;
&#xD;
          -  Have no evidence of Mild Cognitive Impairment (MCI) or dementia, as assessed by the&#xD;
             Montreal Cognitive Assessment score &gt;=26.&#xD;
&#xD;
          -  Have adequate mental health (no self-reported diagnoses of mental illness that would&#xD;
             interfere with ability to comply with study procedures or benefit from intervention)&#xD;
&#xD;
          -  Wiling to complete all study activities&#xD;
&#xD;
          -  Ability to understand study procedures and comply with them for the length of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in another randomized clinical trial, treatment trial, or another&#xD;
             research study that assesses cognition&#xD;
&#xD;
          -  Previous participation in a cognitive training study&#xD;
&#xD;
          -  Self-reported vision, hearing, or motor difficulties that would interfere with the&#xD;
             ability to complete the study interventions&#xD;
&#xD;
          -  Self-reported diagnosis of mild cognitive impairment, dementia, stroke, traumatic&#xD;
             brain injury, brain tumor, or a neurological disorder that affects cognition or would&#xD;
             interfere with the ability to benefit from the study intervention (e.g., Parkinson&#xD;
             disease, multiple sclerosis), or any other unstable medical conditions that is&#xD;
             predisposing to imminent cognitive or functional decline (e.g., congestive heart&#xD;
             failure, chronic obstructive pulmonary disorder dependent on oxygen, or undergoing&#xD;
             chemotherapy or radiation).&#xD;
&#xD;
          -  Self-reported use of medications typically prescribed for dementia such as: Namenda,&#xD;
             Memantine, Namzaric, Donepezil, Aricept, Rivastigmine, Exelon, Razadyne, Galantamine,&#xD;
             Reminyl, aducanumab, Aduhlem.&#xD;
&#xD;
          -  Completion of 10 or more hours of a computerized cognitive training program in the&#xD;
             last 5 years such as: Lumosity, Posit Science Brain Fitness, InSight, or Brain HQ,&#xD;
             Lace, CogMed, CogniFit, Happy Neuron, Elevate, or Dakim&#xD;
&#xD;
          -  Severe depressive symptoms (Geriatric Depression Scale score &gt;=5)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerri Edwards, PhD</last_name>
    <phone>813.974.8572</phone>
    <email>usftampapact@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Hudak, PhD</last_name>
    <phone>813.974.8572</phone>
    <email>usftampapact@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew O'Shea</last_name>
      <phone>352-294-8314</phone>
      <email>PACTUF@phhp.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Adam J Woods, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Burk</last_name>
      <phone>904-620-4263</phone>
      <email>PACTJax@unf.edu</email>
    </contact>
    <investigator>
      <last_name>Jody Nicholson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cognitive Aging Lab</last_name>
      <phone>813-974-8572</phone>
      <email>usftampapact@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jerri Edwards, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Lister, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Hudak, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer O'Brien, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aryn Harrison-Bush, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Health</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Chanti-Ketterl, PhD</last_name>
      <phone>919-668-3154</phone>
      <email>PACTStudy@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Brenda Plassman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clemson University Institute for Engaged Aging</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine B Phillips, PhD</last_name>
      <phone>864-916-6220</phone>
      <email>PACT@clemson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Scoles</last_name>
      <phone>864-916-6220</phone>
      <email>PACT@clemson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lesley A Ross, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>March 24, 2022</last_update_submitted>
  <last_update_submitted_qc>March 24, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Jerri D. Edwards</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03848312/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

